Diabetic

This drug has shown a 77.20 per cent ulcer closure rate in clinical trials, offering hope for a condition that often leads to severe outcomes like lower limb amputations

Indians need simple, easy-to-understand, and prominent warning labels, so that their better natures are given a chance to overtake their impulses

Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W

The study was published in Proceedings of the National Academy of Science

The findings, published in JAMA Network Open, showed that men were more likely to develop diabetes than women

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

Glenmark Pharmaceuticals on Thursday said it has launched a fixed-dose combination for the treatment of diabetes for patients with comorbidities. The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes. Marketed under the brand name Zita D, it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control and prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities, Glenmark Pharma said in a statement. "Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities," Glenmark Pharmaceuticals EVP & Business Head India Formulations Alok Malik said. The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control

The Union Ministry of Health has made amendments to the Drugs Rules, 1945, to implement this

Research by independent group warns against rise in respiratory diseases and economic loss if air pollution increases.

In severe cases, it can lead to potentially serious complications such as gangrenous wounds that necessitate the amputation of a toe, foot or leg

The prices have already dropped by almost 80% in most cases.

With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease, the statement said.

Foods low on glycemic index and high on fibre can be just as delectable as normal restaurant fare. And you needn't ditch your dessert, as there are plenty of diabetic-friendly options here too

Jaynish (name changed), a 38-year-old investment banker, was diagnosed with diabetes four years ago. Due to his failure to respond to three oral antidiabetic drugs, he was prescribed four shots of insulin a day and was on these for over a year. In the past year, he complained of shortness of breath on exertion and swelling around the ankles. He was diagnosed with heart disease and was immediately started on medications for high blood pressure and cholesterol. Though he made major changes in his lifestyle, which improved his glucose control, the insulin shots continued to interfere with his professional and personal life. Heart disease is the No 1 cause of death among people with Type 2 diabetes. There is also striking evidence that diabetes is related to obesity. Among Indians, particularly, the problem of central obesity, or fat deposition around the stomach area, is high. This central obesity is largely responsible for poor glucose control and also has a direct link to heart disease.